Last ¥4,655 JPY
Change Today +30.00 / 0.65%
Volume 121.1K
4536 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
Frankfurt
OTC US
As of 1:45 AM 04/18/14 All times are local (Market data is delayed by at least 15 minutes).

santen pharmaceutical co ltd (4536) Snapshot

Open
¥4,645
Previous Close
¥4,625
Day High
¥4,655
Day Low
¥4,615
52 Week High
10/22/13 - ¥5,050
52 Week Low
05/31/13 - ¥3,920
Market Cap
384.4B
Average Volume 10 Days
386.7K
EPS TTM
¥215.22
Shares Outstanding
82.6M
EX-Date
03/27/14
P/E TM
21.6x
Dividend
¥100.00
Dividend Yield
2.17%
Current Stock Chart for SANTEN PHARMACEUTICAL CO LTD (4536)

Related News

No related news articles were found.

santen pharmaceutical co ltd (4536) Related Businessweek News

No Related Businessweek News Found

santen pharmaceutical co ltd (4536) Details

Santen Pharmaceutical Co., Ltd. is engaged in the research, development, manufacture, and marketing of ophthalmic and anti-rheumatic pharmaceuticals for the protection and enhancement of eyesight and health. The company offers various prescription pharmaceuticals in the areas, such as corneal and conjunctival epithelial disorders; glaucoma; retinal and uveal disorders; ocular infections/allergy; and rheumatoid arthritis. It also provides over-the-counter pharmaceuticals; and medical devices, such as intraocular lenses and injectors. Santen Pharmaceutical Co., Ltd. offers its products in Japan, rest of Asia, Europe, and North America. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

3,050 Employees
Last Reported Date: 06/25/13
Founded in 1890

santen pharmaceutical co ltd (4536) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

santen pharmaceutical co ltd (4536) Key Developments

Santen Pharmaceutical Co. Ltd Announces Phase III Data for Opsiria in Uveitis

Santen Pharmaceutical Co. Ltd. published positive data from a Phase III trial studying Opsiria (intravitreal sirolimus) as a treatment for non-infectious posterior-segment uveitis (NI-PSU). The data was from study 1 of the ongoing SAKURA trial testing Opsiria's safety and efficacy in 347 patients. The primary endpoint of achieving a vitreous haze score of 0 was reached. Opsiria, an mTOR inhibitor, is a proprietary ocular formulation of sirolimus, which has already been approved by the US FDA in two other products - immunosuppressive drug Rapamune, in use for renal transplant patients; and the drug-eluting coronary stent Cypher, a treatment to improve coronary luminal diameter in patients with ischaemic heart disease. The encouraging results indicated Santen may be moving closer to providing a treatment for uveitis, a serious intraocular inflammatory condition associated with significant morbidity, and currently treated by steroids and systemic immunosuppressants.

Santen Partners with Oak Pharmaceuticals for Marketing of Tafluprost in the U.S

Santen Pharmaceutical Co. Ltd. signed a licensing agreement with Oak Pharmaceuticals Inc. pertaining to the sales and marketing in the United States of tafluprost, the treatment of glaucoma and elevated intraocular pressure. Tafluprost is trademarked as ZIOPTAN in the U.S. and TAPROS in Japan. Oak Pharmaceuticals recently acquired tafluprost business from Merck & Co. Inc. and has been granted the rights to sell and market tafluprost in the U.S. by Santen pursuant to the Agreement. Under the Agreement, Santen has certain rights to receive royalties on sales of ZIOPTAN from Oak Pharmaceuticals.

Santen Pharmaceutical Co. Ltd. Announces Executive Changes

Santen Pharmaceutical Co. Ltd. announced the appointment of Sadatoshi Furukado as Director, Vice President and Executive Corporate Officer of Japan Business and Human Resources Development from Director, Executive Corporate Officer of Japan Business and Human Resources Development and Head of Sales and Marketing Division, Prescription Pharmaceuticals; Masamichi Sato as Senior Corporate Officer, Head of Santen European Group and President of Santen Holdings EU B.V. from Senior Corporate Officer, Head of Santen European Group and President of Santen Holdings EU B.V.; Takeshi Ito as Senior Corporate Officer of Head of Sales and Marketing Division, Prescription Pharmaceuticals from Corporate Officer, Head of Prescription of Pharmaceuticals Sales Dept., Sales and Marketing Division of Prescription Pharmaceuticals; Kenji Morishima as Corporate Officer and Head of Global Pharmaceutical Technology Development from Corporate Officer and Head of Human Resources Development and CSR Division; Atsutoshi Ota as Corporate Officer and Head of Human Resources Development and CSR Division from Corporate Officer and Head of Product Supply Division; Kazuo Koshiji as Corporate Officer, Chief Financial Officer and Head of Finance and Administration Division from Corporate Officer and Head of Finance and Administration Division; Noriaki Yamamoto as Corporate Officer, Chief Information Officer and Head of Information Systems Division from Head of Information Systems Division; Hiroyuki Yamazaki as Corporate Officer, Head of Prescription Pharmaceuticals Sales Dept., Sales and Marketing Division, Prescription Pharmaceuticals from Area Manager, Chubu Area, Prescription Pharmaceuticals Sales Dept., Sales and Marketing Division, Prescription Pharmaceuticals; and Keizo Nakada as Corporate Officer and Head of Product Supply Division from Head of Manufacturing Department.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4536:JP ¥4,655.00 JPY +30.00

4536 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €10.70 EUR -0.10
Cubist Pharmaceuticals Inc $63.95 USD +0.02
Salix Pharmaceuticals Ltd $101.06 USD +0.40
Synergy Health PLC 1,241 GBp -8.00
Theravance Inc $26.47 USD -0.66
View Industry Companies
 

Industry Analysis

4536

Industry Average

Valuation 4536 Industry Range
Price/Earnings 22.2x
Price/Sales 2.8x
Price/Book 2.2x
Price/Cash Flow 22.0x
TEV/Sales 2.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTEN PHARMACEUTICAL CO LTD, please visit www.santen.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.